PMID- 31295009
OWN - NLM
STAT- MEDLINE
DCOM- 20200115
LR  - 20200115
IS  - 1557-7708 (Electronic)
IS  - 1075-5535 (Linking)
VI  - 25
IP  - 8
DP  - 2019 Aug
TI  - The Efficacy and Safety of Xinmailong Injection in Patients with Chronic Heart 
      Failure: A Multicenter Randomized Double-Blind Placebo-Controlled Trial.
PG  - 856-860
LID - 10.1089/acm.2019.0030 [doi]
AB  - Objectives: Chronic heart failure (CHF) is a chronic and progressive disease with 
      high incidence. The aim of this study was to evaluate the effectiveness and 
      safety of Xinmailong injection (XI) on CHF patients with B-type natriuretic 
      peptide (BNP) >/=200 ng/mL and left ventricular ejection fraction (LVEF) of </=45%. 
      Trial design: This is a randomized double-blind placebo-controlled trial. 
      Settings: Hospitals. Subjects: One hundred patients with CHF were randomly 
      divided into XI (n = 50) and control groups (n = 50). Intervention: The XI group 
      was treated with standard treatment plus XI (100 mg/2 mL, intravenous drip 
      infusion). The control group was treated with standard treatment plus equal 
      amounts of XI placebo. The course of treatment was 5 days. Outcome measures: New 
      York Heart Association (NYHA) functional class, LVEF, BNP, and 6-min walking 
      distance were assessed for therapeutic effect. Results: NYHA functional classes 
      and LVEF were better in the XI group than in the control (p < 0.01). BNP was 
      significantly different after the treatments in both groups (p < 0.01), and 
      compared with the control, BNP was reduced after XI treatment (p < 0.01). No 
      deaths occurred in the course of this study. The number of adverse events between 
      the two groups was not statistically different (p > 0.05). Conclusions: XI can 
      alleviate the symptoms, improve heart function, and exercise tolerance in 
      patients with CHF and is safe to use.
FAU - Xue, Jingui
AU  - Xue J
AD  - 1Department of Cardiology, Shuguang Hospital Affiliated to Shanghai University of 
      Traditional Chinese Medicine, Shanghai, China.
FAU - Xu, Yong
AU  - Xu Y
AD  - 2Department of Cardiology, The Affiliated Hospital of Chengdu University of 
      Traditional Chinese Medicine, Chengdu, China.
FAU - Deng, Yue
AU  - Deng Y
AD  - 3Department of Cardiology, The Affiliated Hospital of Changchun University of 
      Traditional Chinese Medicine, Changchun, China.
FAU - Li, Fengchun
AU  - Li F
AD  - 4Department of Cardiology, Xi'an Hospital of Traditional Chinese Medicine, Xi'an, 
      China.
FAU - Liu, Fan
AU  - Liu F
AD  - 5Department of Cardiology, Chongqing First People's Hospital, Chongqing, China.
FAU - Liu, Li
AU  - Liu L
AD  - 6Department of Cardiology, The First Affiliated Hospital of Heilongjiang 
      University of Chinese Medicine, Harbin, China.
FAU - Wang, Xing
AU  - Wang X
AD  - 6Department of Cardiology, The First Affiliated Hospital of Heilongjiang 
      University of Chinese Medicine, Harbin, China.
FAU - Wang, Jianzhong
AU  - Wang J
AD  - 7Department of Cardiology, Siping Central People's Hospital of Jilin, Siping, 
      China.
FAU - Wang, Xiaolong
AU  - Wang X
AD  - 1Department of Cardiology, Shuguang Hospital Affiliated to Shanghai University of 
      Traditional Chinese Medicine, Shanghai, China.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20190711
PL  - United States
TA  - J Altern Complement Med
JT  - Journal of alternative and complementary medicine (New York, N.Y.)
JID - 9508124
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (xinmailong)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
SB  - IM
MH  - Aged
MH  - Chronic Disease
MH  - Drugs, Chinese Herbal/*adverse effects/*therapeutic use
MH  - Female
MH  - Heart Failure/*drug therapy/physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/blood
MH  - Stroke Volume/physiology
MH  - Treatment Outcome
MH  - Walk Test
OTO - NOTNLM
OT  - B-type natriuretic peptide
OT  - Xinmailong injection
OT  - chronic heart failure
OT  - ventricular ejection fraction
EDAT- 2019/07/12 06:00
MHDA- 2020/01/16 06:00
CRDT- 2019/07/12 06:00
PHST- 2019/07/12 06:00 [pubmed]
PHST- 2020/01/16 06:00 [medline]
PHST- 2019/07/12 06:00 [entrez]
AID - 10.1089/acm.2019.0030 [doi]
PST - ppublish
SO  - J Altern Complement Med. 2019 Aug;25(8):856-860. doi: 10.1089/acm.2019.0030. Epub 
      2019 Jul 11.